RMAT designation is a major regulatory catalyst that meaningfully reduces clinical and approval risk for Allocetra. The upcoming Type B meeting with FDA will be a key near-term catalyst to align on pivotal trial design. Monitor for meeting outcomes and Phase IIb enrollment updates. The 86% bullish analyst consensus may see upward revision on this regulatory milestone.
Price Chart
Executive Summary
Enlivex announced FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Allocetra in age-related knee osteoarthritis, based on statistically significant Phase I/IIa data. The designation provides intensive FDA engagement, potential accelerated approval, and priority review. The company has initiated a Phase IIb trial (n=182) with top-line data expected by end of Q2 2027.
Key Facts
- FDA granted RMAT designation to Allocetra for age-related symptomatic knee osteoarthritis in patients aged 64 and older
- RMAT designation provides potential eligibility for accelerated approval, priority review, and expedited development
- Phase IIb trial plans to enroll 182 primary knee OA patients aged 64+ in the US and EU
- Top-line data from Phase IIb expected by end of Q2 2027
- FDA requested a Type B meeting for comprehensive multidisciplinary discussion of the development program
- Phase I/IIa showed statistically significant and clinically meaningful improvements in knee pain and physical function vs placebo, durable through at least 6 months
Financial Impact
RMAT designation significantly de-risks the Allocetra program and opens a potential accelerated approval pathway for a large addressable market (32M+ Americans with OA, projected 78M by 2040). No financial terms disclosed.
Risk Factors
- Phase IIb trial may fail to replicate Phase I/IIa efficacy results
- Type B meeting could result in FDA requiring additional preclinical or clinical work before pivotal trial
- Company's dual strategy (biotech + prediction markets treasury) introduces idiosyncratic risk from RAIN token volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-077364 |
| Document: ea029772501-6k_enlivex.htm | 0001213900-26-077364 |
| Document: 0001213900-26-077364-index-headers.html | 0001213900-26-077364 |
| Document: 0001213900-26-077364-index.html | 0001213900-26-077364 |
| Document: 0001213900-26-077364.txt | 0001213900-26-077364 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $0.1734 | awaiting T+5 | — | — |
Oct 22, 2026 4d ago | Press Release | $0.1734 | awaiting T+5 | — | — |
Oct 19, 2026 7d ago | 6-K | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | — |
Oct 19, 2026 7d ago | Press Release | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | — |
Sep 25, 2026 4w ago | 6-K | $0.5140 $0.3620 | ▼ −29.57% | ▼ −30.78% | — |
Sep 22, 2026 4w ago | 6-K | $0.6464 $0.4801 | ▼ −25.73% | ▼ −24.54% | — |
Aug 14, 2026 10w ago | EFFECT | $1.58 $1.47 | ▼ −6.96% | ▼ −5.59% | — |
Jul 30, 2026 12w ago | 6-K | $1.95 $1.98 | ▲ +1.54% | ▼ −2.08% | — |
Jul 29, 2026 12w ago | 6-K | $2.25 $2.18 | ▼ −3.11% | ▼ −8.64% | — |
Jul 28, 2026 12w ago | 6-K | $2.24 $2.17 | ▲ +3.13% | ▲ +5.39% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers